Fatima Karzai, MD, on Prostate Cancer: Treatment Study Results
2018 Genitourinary Cancers SymposiumFatima Karzai, MD, of the National Institutes of Health, discusses phase II findings on olaparib and durvalumab in metastatic castration-resistant prostate cancer in an unselected population (Abstract 163).
Related Videos
Laurence Albiges, MD, PhD, on RCC: Results From the NIVOREN GETUG-AFU 26 Trial
Laurence Albiges, MD, PhD, of the Gustave Roussy Cancer Centre, discusses study findings on the safety and efficacy of nivolumab in metastatic renal cell carcinoma (Abstract 577).<...
John J. Coen, MD, on Bladder Cancer: Results From the NRG/RTOG 0712 Trial
John J. Coen, MD, of 21st Century Oncology, discusses phase II study findings on selective bladder preservation with twice-daily radiation plus fluorouracil/cisplatin or daily radi...
Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Results From the CheckMate 032 Trial
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses longer-term efficacy and safety findings on nivolumab monotherapy in metastatic urothelial carcinoma...
Gregory R. Pond, PhD, on Urothelial Cancer: Advance in Prognosis
Gregory R. Pond, PhD, of McMaster University, discusses a new six-factor prognostic model for patients with advanced urothelial carcinoma receiving post platinum atezolizumab (Abst...
Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial
Nicholas D. James, MBBS, PhD, of University Hospitals Birmingham NHS Foundation Trust, discusses study findings on the addition of docetaxel to first-line hormone therapy in prosta...
